What they reported doing
- #1 primary $3.86MIMCA-CAT provided an outstanding support environment for macro-molecular crystallography by developing and operating an efficient, reliable , high-throughput facility at which both confidential and proprietary equipment can be readily and easily accommodated.
- #2 $1.19MThe National HTX Center aims to implement a modern internet interface for users of the High-Throughput Crystallization Screening Center to interact with the images of their crystallization screening experiments. A further goal is to begin development of software to enable automatic image analysis and classification.
What they call their work
What they do
-
Biomedical Research and Innovation 3 activities
- Cryo-electron microscopy servicesProvides single-particle and microcrystal electron diffraction services through its Cryo-Electron Microscopy Center to academic, government, non-profit, and industry research organizations.
- Digital infrastructure for crystallography data access and analysisImplements a modern internet interface that allows users to access images from high-throughput crystallization screening experiments and develops software for automated image analysis and classification to support structural biology research.
- High-throughput macromolecular crystallographyDevelops and operates a high-throughput facility for macromolecular crystallography that supports structural biology research and accommodates confidential and proprietary equipment. Provides protein crystallization services to academic, government, and non-profit research institutes.
-
Who runs it
| Name | Title | Hours/wk | Compensation |
|---|---|---|---|
| Edward Snell | Chief Scientific Officer | 38 | $255K |
| Lisa Keefe | VP | 38 | $240K |
| Anne Kent | Chief Financial Officer | 38 | $180K |
| Devrim Acehan | Cryo-EM Director | 38 | $167K |
| Daniel Gewirth | Principal Research Scientist | 38 | $158K |
| John Muir | Software Developer | 38 | $154K |
| Blanca Carbajal | Business Development Director | 38 | $139K |
| Aviv Paz | Principal Investigator | 38 | $132K |
| Sarah Bowman | Board Member/Associate Investigator | 38 | $123K |
| Christopher Greene | Interim CEO | 1 | $120K |
- Andrei Gudkov — Board Member
- Artem Evdokimov — Board Member
- Brenda McDuffie — Board Member
- Christina Arthurs — Board Member
- Dan Magnuszewski — Board Member
- EJ Burke — Board Member
- Franca Trincia — Board Member
- Frank Ewing — Board Member
- Jeffrey Renzoni — Board Member
- Jill Bond — Board Member/Secretary
- LaVonne Ansari — Board Member
- Michele Heffernan — Board Member
- Nena Rich — Board Member
- Philip Nobel — Board Member
- Sam Russo — Board Member/Chairperson of the Board
Who they work with
- IMCA-CAT Partner — Collaborates on providing a high-throughput facility for macro-molecular crystallography.
- National Institutes of Health Government — Primary funder of the National Crystallization Center.
How they approach the work
Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.
- Basic and Fundamental Research as Foundation for Therapeuticsmethodology: basic_research_foundationBy conducting basic, fundamental research, we enable the long-term development of effective therapeutic approaches, because foundational scientific discoveries create the necessary knowledge base for future applied innovations and medical breakthroughs.
- Shared Research Infrastructure Modelmethodology: shared_research_infrastructureBy providing external research organizations access to advanced, specialized facilities and services (e.g., protein crystallization and cryo-electron microscopy), we accelerate structural biology research across diverse scientific communities, because centralized, expert-maintained infrastructure reduces duplication, lowers barriers to high-resolution analysis, and enables research that would otherwise be infeasible for individual institutions.
- Targeted Protein Research for Therapeuticsmethodology: targeted_protein_researchBy identifying disease-related proteins, we enable the development of more effective, targeted therapeutic approaches, because understanding the molecular targets of disease allows for precise intervention and drug design.